Sign In
Buy IMGN
$31.23
+0 (+0%)
At Close: May 08, 2024
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
12:24pm, Monday, 01'st Aug 2022
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
ImmunoGen (IMGN) Q2 2022 Earnings Call Transcript
03:30pm, Saturday, 30'th Jul 2022 The Motley Fool
IMGN earnings call for the period ending June 30, 2022.
ImmunoGen, Inc. (IMGN) CEO Mark Enyedy on Q2 2022 Results - Earnings Call Transcript
11:45am, Friday, 29'th Jul 2022
ImmunoGen, Inc. (NASDAQ:IMGN ) Q2 2022 Results Conference Call July 29, 2022 8:00 AM ET Company Participants Anabel Chan - Head of Investor Relations Mark Enyedy - President, CEO Anna Berkenblit - CMO
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
11:45am, Friday, 29'th Jul 2022 Zacks Investment Research
ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen (IMGN) Reports Q2 Loss, Lags Revenue Estimates
09:21am, Friday, 29'th Jul 2022
ImmunoGen (IMGN) delivered earnings and revenue surprises of -9.09% and 16.74%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
ImmunoGen: Possible Accelerated FDA Approval For Ovarian Cancer Treatment
02:51pm, Monday, 20'th Jun 2022
PDUFA date with Priority Review for mirvetuximab for treatment of ovarian cancer patients with high folate receptor alpha set for November 28, 2022. Confirmatory MIRASOL study trial readout of mirvetu
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
02:02pm, Tuesday, 14'th Jun 2022 Zacks Investment Research
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
ImmunoGen (IMGN) Enters New Collaboration to Boost ADC Pipeline
11:36am, Tuesday, 14'th Jun 2022
ImmunoGen (IMGN) inks a collaboration deal with privately-held Oxford BioTherapeutics to develop novel antibody-drug conjugates by complementing each other's proprietary technologies.
ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
04:30pm, Wednesday, 25'th May 2022
WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
01:39pm, Tuesday, 24'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
ImmunoGen (IMGN) Ovarian Cancer Drug BLA Gets Priority Review
11:18am, Tuesday, 24'th May 2022
ImmunoGen (IMGN) gets priority review from the FDA for the BLA seeking approval for its lead candidate, mirvetuximab soravtansine, for treating platinum-resistant ovarian cancer.
What's Going On With ImmunoGen Shares Today?
12:40pm, Monday, 23'rd May 2022
ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review. ImmunoGen's BLA
ImmunoGen's stock is up 12% after the FDA accepts application for new ovarian-cancer therapy
07:59am, Monday, 23'rd May 2022
Shares of ImmunoGen Inc. IMGN, +1.42% jumped 12.0% in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer tr
ImmunoGen: An Inflection Point In Growth
04:16pm, Tuesday, 17'th May 2022
ImmunoGen is a promising turnaround equity that is approaching its inflection point in growth. Mirvetuximab is poised to gain approval toward yearend.
ImmunoGen (IMGN) Q1 Earnings and Sales Outpace Estimates
03:21pm, Monday, 09'th May 2022 Zacks Investment Research
ImmunoGen (IMGN) reports a narrower-than-expected loss for first-quarter 2022. It also beats revenue estimates.
